Rapid determination of apixaban concentration in human plasma by liquid chromatography/tandem mass spectrometry: Application to pharmacokinetic study

Journal of Pharmaceutical and Biomedical Analysis

Volumn 78-79, Issue , 2013, Pages 150-153

  Delavenne, Xavier ^a,b   Mismetti, Patrick ^b   Basset, Thierry ^a,b  

^a UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^b University Jean Monnet of Saint Etienne EA3065   (France)

Author keywords

Anticoagulants; Apixaban; Direct factor Xa inhibitors; Liquid chromatography; Tandem mass spectrometry

Indexed keywords

APIXABAN;

AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG STABILITY; ELECTROSPRAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; REVERSED PHASE LIQUID CHROMATOGRAPHY; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

ANTITHROMBINS; CHROMATOGRAPHY, LIQUID; HUMANS; PYRAZOLES; PYRIDONES; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY;

EID: 84875253725     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2013.02.007     Document Type: Article

References (15)

1. Wang L., Zhang D., Raghavan N., Yao M., Ma L., Frost C.A., et al. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab. Dispos. 2010, 38:448-458.
2. Connolly S.J., Eikelboom J., Joyner C., Diener H.-C., Hart R., Golitsyn S., Flaker G., Avezum A., Hohnloser S.H., Diaz R., Talajic M., Zhu J., Pais P., Budaj A., Parkhomenko A., Jansky P., Commerford P., Tan R.S., Sim K.H., Lewis B.S., Van Mieghem W., Lip G.Y., Kim J.H., Lanas- Zanetti F., Gonzalez-Hermosillo A., Dans A.L., Munawar M., O'Donnell M., Lawrence J., Lewis G., Afzal R., Yusuf S., AVERROES Steering Committee and Investigators Apixaban in patients with atrial fibrillation. N. Engl. J. Med. 2011, 364:806-817.
3. Jiang X., Crain E.J., Luettgen J.M., Schumacher W.A., Wong P.C. Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro. Thromb. Haemost. 2009, 101:780-782.
4. Kubitza D., Haas S. Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases. Expert Opin. Investig. Drugs 2006, 15:843-855.
5. Fauchier L., Clementy N. Apixaban after acute coronary syndrome. N. Engl. J. Med. 2011, 365. 1844-author reply-1845-5.
6. Nutescu E., Rhoades R., Bailey C., Zhou S. Apixaban: a novel oral inhibitor of factor Xa. Am. J. Health. Syst. Pharm. 2012, 69:1113-1126.
7. Raghavan N., Frost C.E., Yu Z., He K., Zhang H., Humphreys W.G., Humphreys W.G., Pinto D., Chen S., Bonacorsi S., Wong P.C., Zhang D. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab. Dispos. 2008, 37:74-81.
8. Wong P.C., Pinto D.J.P., Zhang D. Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor. J. Thromb. Thrombolysis 2011, 31:478.
9. Baglin T., Keeling D., Kitchen S. Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology. Br. J. Haematol. 2012, 159:427-429.
10. FDA, Guidance for Industry, Bioanalytical Method Validation, 2001.
11. Delavenne X., Gay-Montchamp J.P., Basset T. HPLC MS/MS method for quantification of meprobamate in human plasma: application to 24/7 clinical toxicology. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2011, 879:215-218.
12. Delavenne X., Moracchini J., Laporte S., Mismetti P., Basset T. UPLC MS/MS assay for routine quantification of dabigatran - a direct thrombin inhibitor - in human plasma. J. Pharm. Biomed. Anal. 2012, 58:152-156.
13. Leil T.A., Feng Y., Zhang L., Paccaly A., Mohan P., Pfister M. Quantification of apixaban's therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose. Clin. Pharmacol. Ther. 2010, 88:375-382.
14. Frost C., Wang J., Nepal S., Schuster A., Barrett Y.C., Mosqueda-Garcia R., Reeves R.A., Lacreta F. Apixaban, an oral, direct factor Xa inhibitor: single-dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br. J. Clin. Pharmacol. 2013, 75:476-487.
15. Barrett Y.C., Wang J., Song Y., Pursley J., Wastall P., Wright R., Lacreta F., Frost C. A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects. Thromb. Haemost. 2012, 107:916-924.